Iovance Biotherapeutics (NASDAQ:IOVA) Releases Earnings Results, Beats Expectations By $0.04 EPS

Iovance Biotherapeutics (NASDAQ:IOVA) issued its earnings results on Tuesday. The biotechnology company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.04, FiscalAI reports. The business had revenue of $86.77 million during the quarter, compared to analysts’ expectations of $81.61 million. Iovance Biotherapeutics had a negative net margin of 148.41% and a negative return on equity of 54.09%.

Here are the key takeaways from Iovance Biotherapeutics’ conference call:

• Iovance reported ~30% revenue growth in 2025 with Q4 product revenue of $87M, full-year revenue of ~ $264M, a record Q4 gross margin of 50% from cost of sales, and approximately $303M in cash providing runway into Q3 2027.
• Commercial momentum for Amtagvi accelerated with expanding academic and community ATCs, rising demand and operational improvements, and management expects “remarkable” 2026 revenue growth and a U.S. peak sales opportunity of >$1B for Amtagvi (with Proleukin complementing demand).
• Pipeline advances include Fast Track designation for lifileucel in previously treated non-squamous NSCLC (ORR 26%, median DOR not reached) targeting an sBLA and potential accelerated approval/launch in H2 2027, and a pilot in two soft-tissue sarcoma subtypes showed a 50% confirmed response rate with a registrational trial planned.
• Operational improvements and full internalization of manufacturing at the ICTC improved manufacturing success, reduced dropouts, converted the facility to a modular scalable model, and management said these steps materially supported margin expansion without major new capital expenditures.
• The company did not provide full-year 2026 revenue guidance on the call but said detailed total product guidance will be issued “very soon,” and noted Proleukin has contributed roughly 16–17% of 2025 revenue as the commercial mix stabilizes.

Iovance Biotherapeutics Stock Performance

Shares of Iovance Biotherapeutics stock traded down $0.25 during trading hours on Thursday, hitting $3.59. The company’s stock had a trading volume of 5,590,699 shares, compared to its average volume of 13,445,042. The stock has a market cap of $1.42 billion, a price-to-earnings ratio of -3.19 and a beta of 0.76. Iovance Biotherapeutics has a twelve month low of $1.64 and a twelve month high of $5.64. The firm has a fifty day moving average of $2.67 and a 200-day moving average of $2.41.

Iovance Biotherapeutics News Summary

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Q4 results beat expectations: narrower loss, roughly $86–87M revenue, strong Amtagvi sales growth and management announced pipeline progress (50% ORR in early sarcoma data and plans for a registrational sarcoma study) — a primary driver of the recent rally. IOVA Beats on Q4 Earnings & Sales
• Positive Sentiment: Positive early soft‑tissue sarcoma trial data sparked sharp intraday moves and retail/sector interest — this clinical readout is being treated as a potential expansion of lifileucel’s label and a material upside driver. Iovance Biotherapeutics Explodes Over 20%
• Positive Sentiment: Analyst bullishness: HC Wainwright kept a Buy and materially raised FY2026/FY2027 EPS forecasts (improving modeled losses) and several firms raised or upgraded price targets — adds legitimacy to the upside narrative. MarketBeat IOVA analyst notes
• Neutral Sentiment: Company will present at upcoming conferences — useful for incremental investor outreach and visibility but not immediately material. Iovance to Present at Upcoming Conferences
• Neutral Sentiment: Unusually large options activity — a big increase in call buying indicates speculative bullish positioning and may amplify intraday moves but doesn’t change fundamentals. Iovance Sees Unusually Large Options Volume
• Negative Sentiment: Short interest surged in February to ~36.9% of float with a ~14.6 day short‑interest ratio — this amplifies volatility and raises the risk of sharp squeezes or outsized downward pressure if sentiment turns. (Short interest data reported Feb. 13.)
• Negative Sentiment: Cash runway and dilution risk remain concerns raised by analysts: while margins and turnaround improved, modeled profitability is still years away and additional financing or partnerships may be needed. Seeking Alpha: Better Gross Margin And Faster Turnaround

Analyst Ratings Changes

A number of research firms have commented on IOVA. HC Wainwright cut their price objective on shares of Iovance Biotherapeutics from $20.00 to $9.00 and set a “buy” rating for the company in a report on Wednesday, October 29th. The Goldman Sachs Group reaffirmed a “sell” rating and issued a $2.00 price target on shares of Iovance Biotherapeutics in a report on Thursday, February 5th. Chardan Capital reduced their price objective on Iovance Biotherapeutics from $17.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday. Barclays upped their target price on Iovance Biotherapeutics from $10.00 to $11.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, Citizens Jmp upgraded Iovance Biotherapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price target on the stock in a report on Wednesday. Six research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $10.00.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of IOVA. BNP Paribas Financial Markets boosted its position in shares of Iovance Biotherapeutics by 79.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 41,623 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 18,471 shares during the period. Russell Investments Group Ltd. lifted its stake in Iovance Biotherapeutics by 372.4% during the second quarter. Russell Investments Group Ltd. now owns 40,347 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 31,807 shares in the last quarter. Xponance LLC boosted its position in shares of Iovance Biotherapeutics by 19.4% during the fourth quarter. Xponance LLC now owns 24,288 shares of the biotechnology company’s stock worth $66,000 after buying an additional 3,950 shares during the period. CIBC Bancorp USA Inc. acquired a new stake in shares of Iovance Biotherapeutics in the third quarter valued at $60,000. Finally, Jump Financial LLC purchased a new stake in shares of Iovance Biotherapeutics in the 4th quarter valued at $60,000. Institutional investors and hedge funds own 77.03% of the company’s stock.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.